Initiate bioequivalence study of Renazorb
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 May 2022
- Due
- 30 Jun 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Unicycive plans to enroll the first subject in a bioequivalence (BE) study in healthy volunteers to demonstrate the comparability of Renazorb to the reference listed drug, Fosrenol, in the second quarter.”
What we found
Evidence strength A What the grades mean
The company confirmed in an August 2022 filing that it initiated the bioequivalence study for Renazorb during the second quarter of 2022, meeting its stated commitment.
-
A Unicycive Therapeutics, Inc. 8-K filed 2022-08-15
“During the second quarter, Unicycive initiated a bioequivalence (BE) study in healthy volunteers to demonstrate the comparability of Renazorb to the reference listed drug, Fosrenol.” ✓ confirmed on the page
Market reaction: the shares moved -3.0% against the S&P 500 over the three sessions around the disclosure (12 Aug 2022 to 17 Aug 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Renazorb bioequivalence study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-UNCY-002769 · Corrections policy